Ciclopirox olamine

环吡酮胺

Report date: 2023/01/13 20:00:32
NME

Base Information

Drug NameCiclopirox olamine
Drug Alias NameDafnegin环匹罗司Ciclopiroxolamine环吡司胺环吡司乙醇胺 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsDermatitis, SeborrheicMyelodysplastic Syndromes +[12] 
Global Approved IndicationsDermatitis, SeborrheicCandidiasis, VulvovaginalMycoses
Approved Indications in ChinaDermatitis, SeborrheicCandidiasis, VulvovaginalMycoses
Original Approved Country/TerritoryCanada
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesAtlas Molecular PharmaHubei Ketian Pharmaceutical Co LtdHubei Keyi Pharmaceutical Co Ltd
Inactive CompaniesPadagis LLCUniversity Health Network (Uhn)Jumpcan Pharmaceutical Group Co Ltd
Active IndicationsDrug-Related Side Effects and Adverse ReactionsDermatitis, SeborrheicCandidiasis, Vulvovaginal +[4] 
Inactive IndicationsMyelodysplastic SyndromesHematologic NeoplasmsHodgkin Disease +[8] 

Other Information

ATC CodeD01AE14G01AX12
Related LinksWikipediaDrugBankKEGG